Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.

Saved in:
Bibliographic Details
Title: Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.
Authors: Flanigan J; Sandoz Inc, 100 College Road West, Princeton, NJ, 08540, USA., Kane S; Value and Evidence, EVERSANA, 204-3228 South Service Road, Burlington, ON, L7N 3H8, Canada., Mirzayeh Fashami F; Value and Evidence, EVERSANA, 204-3228 South Service Road, Burlington, ON, L7N 3H8, Canada., Zhou A; Value and Evidence, EVERSANA, 204-3228 South Service Road, Burlington, ON, L7N 3H8, Canada., Almuallem L; Value and Evidence, EVERSANA, 204-3228 South Service Road, Burlington, ON, L7N 3H8, Canada., Tindal M; Sandoz Inc, 100 College Road West, Princeton, NJ, 08540, USA., Schauf M; Sandoz International GmbH, Industriestr. 25, 83607, Holzkirchen, Bayern, Germany., Li E; Sandoz Inc, 100 College Road West, Princeton, NJ, 08540, USA. edward-1.li@sandoz.com., Lyman GH; Duke University School of Medicine, 2424 Erwin Rd, Box 2736, Durham, NC, 27705, USA.
Source: PharmacoEconomics - open [Pharmacoecon Open] 2026 Jul; Vol. 10 (4), pp. 733-748. Date of Electronic Publication: 2026 Apr 14.
Publication Type: Journal Article
Journal Info: Publisher: Springer International Publishing AG Country of Publication: Switzerland NLM ID: 101700780 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2509-4254 (Electronic) Linking ISSN: 25094262 NLM ISO Abbreviation: Pharmacoecon Open Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2509-4254
DOI:10.1007/s41669-026-00651-0